Banbury Partners Has Decreased By $858,705 Its Amerco (UHAL) Holding; Regulus Therapeutics (RGLS) SI Decreased By 4.09%

June 10, 2018 - By Richard Conner

Regulus Therapeutics Inc. (NASDAQ:RGLS) Logo

Regulus Therapeutics Inc (NASDAQ:RGLS) had a decrease of 4.09% in short interest. RGLS’s SI was 1.70 million shares in June as released by FINRA. Its down 4.09% from 1.78 million shares previously. With 630,100 avg volume, 3 days are for Regulus Therapeutics Inc (NASDAQ:RGLS)’s short sellers to cover RGLS’s short positions. The SI to Regulus Therapeutics Inc’s float is 2.79%. The stock decreased 0.91% or $0.0066 during the last trading session, reaching $0.7202. About 122,800 shares traded. Regulus Therapeutics Inc. (NASDAQ:RGLS) has declined 45.33% since June 10, 2017 and is downtrending. It has underperformed by 57.90% the S&P500. Some Historical RGLS News: ; 07/03/2018 – REGULUS THERAPEUTICS INC – QTRLY NET LOSS PER SHARE $0.14; 01/05/2018 – Regulus Cyber Wins AUVSI XCELLENCE Award; 07/03/2018 – Regulus Therapeutics: Full Enrollment of RG-012 Studies Anticipated in 2H; 01/05/2018 – Regulus Therapeutics: Initial Safety and Pharmacokinetic Results From Single Ascending Dose Study Support Advancement; 07/03/2018 Regulus Therapeutics 4Q Loss/Shr 14c; 17/04/2018 – Kathryn J. Collier Joins Regulus Board of Directors; 07/03/2018 – Regulus Therapeutics 4Q Loss $14.4M; 01/05/2018 – Regulus Cyber Raises $6.3M to Ensure Security & Mission Reliability for Autonomous Cars & Trucks, Robots, and Drones; 01/05/2018 – Regulus Initiates Multiple Ascending Dose Study in Healthy Volunteers of RGLS4326 for the Treatment of ADPKD; 13/04/2018 – Regulus Steps to North and Intercepts 258 Metres With 0.43% Cu, 0.29 g/t Au and 4.62 g/t Ag (0.68% Cueq) at AntaKori, Peru

Banbury Partners Llc decreased Amerco (UHAL) stake by 5.19% reported in 2018Q1 SEC filing. Banbury Partners Llc sold 2,489 shares as Amerco (UHAL)’s stock rose 0.54%. The Banbury Partners Llc holds 45,511 shares with $15.71 million value, down from 48,000 last quarter. Amerco now has $6.80 billion valuation. The stock increased 0.99% or $3.39 during the last trading session, reaching $346.68. About 118,896 shares traded or 54.22% up from the average. AMERCO (NASDAQ:UHAL) has risen 1.27% since June 10, 2017 and is uptrending. It has underperformed by 11.30% the S&P500. Some Historical UHAL News: ; 30/03/2018 – U-Haul Reveals Plans for Former Hardie-Tynes Co. in Birmingham; 30/05/2018 – AMERCO 4Q ADJ LOSS/SHR 28C; 23/03/2018 – U-Haul Announces Plans for Sprawling Eagles Landing Warehouse; 05/04/2018 – Amerco Closes Above 50-Day Moving Average: Technicals; 27/03/2018 – U-Haul Offers 30 Days Free Self-Storage to St. Louis Flood Victims; 30/05/2018 – AMERCO 4Q EPS 56C; 16/05/2018 – U-Haul Reveals Plans for Newest Company-Owned Facility in Southern Louisiana; 27/04/2018 – Adaptive Reuse: U-Haul Repurposing Vacant Kmart for Self-Storage in Yakima; 30/04/2018 – Growing Joplin: U-Haul Adding New Self-Storage, Jobs with Warehouse Acquisition; 30/05/2018 – AMERCO 4Q REV. $757.6M

Since December 18, 2017, it had 0 insider buys, and 1 sale for $76,232 activity. $76,232 worth of AMERCO (NASDAQ:UHAL) was sold by Brogan John P. on Monday, December 18.

Among 2 analysts covering AMERCO (NASDAQ:UHAL), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. AMERCO had 2 analyst reports since August 5, 2016 according to SRatingsIntel. The stock of AMERCO (NASDAQ:UHAL) has “Hold” rating given on Friday, April 6 by C.L. King. The stock has “Buy” rating by CL King on Friday, August 5.

Investors sentiment increased to 1.5 in Q1 2018. Its up 0.31, from 1.19 in 2017Q4. It increased, as 21 investors sold UHAL shares while 53 reduced holdings. 30 funds opened positions while 81 raised stakes. 6.85 million shares or 6.07% more from 6.46 million shares in 2017Q4 were reported. Shell Asset Mgmt accumulated 0% or 203 shares. Gulf Int Natl Bank (Uk) Ltd has invested 0.01% in AMERCO (NASDAQ:UHAL). Third Avenue Management Lc, a New York-based fund reported 87,224 shares. Strs Ohio holds 0% in AMERCO (NASDAQ:UHAL) or 100 shares. Toronto Dominion Fincl Bank reported 0% in AMERCO (NASDAQ:UHAL). Systematic Financial Limited Partnership invested in 53,240 shares or 0.41% of the stock. First Manhattan invested in 362,592 shares. Mutual Of America Limited Liability Company has 761 shares. State Street reported 132,981 shares. British Columbia Inv Management Corp reported 4,356 shares or 0.01% of all its holdings. Moreover, Art Advisors Ltd Limited Liability Company has 0.01% invested in AMERCO (NASDAQ:UHAL). Oregon Pub Employees Retirement Fund invested 0.01% in AMERCO (NASDAQ:UHAL). Vanguard stated it has 0.01% in AMERCO (NASDAQ:UHAL). Dimensional Fund Advsrs LP stated it has 0.06% in AMERCO (NASDAQ:UHAL). Tower Capital Ltd (Trc) invested in 0.01% or 183 shares.

Analysts await AMERCO (NASDAQ:UHAL) to report earnings on August, 8. They expect $7.82 earnings per share, up 21.43% or $1.38 from last year’s $6.44 per share. UHAL’s profit will be $153.34 million for 11.08 P/E if the $7.82 EPS becomes a reality. After $0.56 actual earnings per share reported by AMERCO for the previous quarter, Wall Street now forecasts 1,296.43% EPS growth.

More notable recent AMERCO (NASDAQ:UHAL) news were published by: Seekingalpha.com which released: “Amerco slides 9.9% post Q4 results” on May 31, 2018, also Seekingalpha.com with their article: “White Space And Parallel Investments” published on May 27, 2018, Benzinga.com published: “58 Biggest Movers From Yesterday” on June 01, 2018. More interesting news about AMERCO (NASDAQ:UHAL) were released by: Seekingalpha.com and their article: “Emerging Value Capital Management Q1 – Howard Hughes Sold, Tesla Short Closed; New Long Positions” published on May 24, 2018 as well as Benzinga.com‘s news article titled: “Earnings Scheduled For May 30, 2018” with publication date: May 30, 2018.

Regulus Therapeutics Inc., a biopharmaceutical company, focuses on the discovery and development of drugs that target microRNAs to treat a range of diseases in the United States. The company has market cap of $75.13 million. The firm uses its microRNA product platform to develop anti-miRs, which are chemically modified and single-stranded oligonucleotides. It currently has negative earnings. The Company’s clinical development products include RG-101, a GalNAc-conjugated anti-miR targeting miR-122 to treat patients with hepatitis C virus infection; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome; RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107 for the treatment of non-alcoholic fatty liver disease; RGLS5040, an anti-miR targeting microRNA-27 for the treatment of cholestatic disease; and RGLS4326, an anti-miR targeting microRNA-17 for the treatment of autosomal dominant polycystic kidney disease.

Among 9 analysts covering Regulus Therapeutics (NASDAQ:RGLS), 3 have Buy rating, 0 Sell and 6 Hold. Therefore 33% are positive. Regulus Therapeutics had 33 analyst reports since August 5, 2015 according to SRatingsIntel. The rating was downgraded by Chardan Capital Markets to “Neutral” on Wednesday, August 2. Wedbush maintained it with “Outperform” rating and $8 target in Monday, January 30 report. The firm has “Market Perform” rating given on Wednesday, August 2 by BMO Capital Markets. BMO Capital Markets maintained the stock with “Hold” rating in Monday, June 12 report. The stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) earned “Buy” rating by Chardan Capital Markets on Wednesday, December 7. The stock of Regulus Therapeutics Inc. (NASDAQ:RGLS) has “Buy” rating given on Wednesday, August 5 by Wedbush. Needham downgraded the shares of RGLS in report on Monday, January 30 to “Hold” rating. The firm has “Buy” rating by Chardan Capital Markets given on Tuesday, June 7. The firm has “Buy” rating given on Tuesday, June 28 by Chardan Capital Markets. As per Wednesday, November 8, the company rating was maintained by BMO Capital Markets.

Regulus Therapeutics Inc. (NASDAQ:RGLS) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.